Anti-GFAP Antibody

Glial fibrillary acidic protein
  • New
Cat #: AFP-001
Alternative Name Glial fibrillary acidic protein
  • Lyophilized Powder
  • Antigen Incl.
  • Type: Polyclonal
    Host: Rabbit
    Reactivity: m, r
      • Peptide (C)RHLGTIPRLSLSR, corresponding to amino acid residues 27-39 of rat Glial fibrillary acidic protein (Accession P47819). Intracellular, cytoplasm.
        Anti-GFAP Antibody
    Accession (Uniprot) Number P47819
    Gene ID 24387
    Peptide confirmation Confirmed by amino acid analysis and mass spectrometry.
    Homology Mouse – 10/13 amino acid residues identical.
    Purity Affinity purified on immobilized antigen.
    Form Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.
    Isotype Rabbit IgG.
    Specificity Will not recognize human Glial fibrillary acidic protein (GFAP).
    Storage before reconstitution The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.
    Reconstitution 25 µl, 50 µl or 0.2 ml double distilled water (DDW), depending on the sample size.
    Antibody concentration after reconstitution 0.8 mg/ml.
    Storage after reconstitution The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).
    Negative control antigen storage before reconstitution Lyophilized powder can be stored intact at room temperature for two weeks. For longer periods, it should be stored at -20°C.
    Negative control antigen reconstitution 100 µl double distilled water (DDW).
    Negative control antigen storage after reconstitution -20°C.
    Preadsorption Control 1 µg peptide per 1 µg antibody.
    Standard quality control of each lot Western blot analysis.
    Applications: if, ih, wb
    May also work in: ic*, ip*
      • Anti-GFAP Antibody
        Western blot analysis of rat brain membranes (lanes 1 and 3), (1:2000) and mouse brain lysate (lanes 2 and 4), (1:400):
        1,2. Anti-GFAP Antibody (#AFP-001).
        3,4. Anti-GFAP Antibody, preincubated with the negative control antigen.
      • Anti-GFAP Antibody
        Expression of GFAP in rat brain
        Immunohistochemical staining of free-floating rat frozen brain sections using Anti-GFAP Antibody (#AFP-001), (1:2000). In rat parietal cortex, GFAP immunoreactivity (green) appears in astrocytes (arrows). Nuclei are stained using DAPI as the counterstain (blue).
        Anti-GFAP Antibody
        Immuno-colocalization of GFAP and AQP4 in rat brain
        Immunohistochemical staining of immersion-fixed, free floating rat brain frozen sections using Anti-GFAP Antibody (#AFP-001), (1:2000) and Anti-Aquaporin 4 (AQP4) (300-314)-ATTO-594 Antibody (#AQP-014-AR), (1:100). A. In rat fornix, GFAP immunoreactivity (green) appears in astrocytic processes. B. In same section, AQP4 staining (red) is detected in blood vessels. C. Merge of panel A and panel B shows colocalization around a large blood vessel (arrows). Nuclei are stained using DAPI as the counterstain (blue).
    References
      • Glial fibrillary acidic protein (GFAP) is a key intermediate filament (IF) III protein responsible for maintaining the mechanical strength of glia cells by supporting their cytoskeleton structure. GFAP is expressed in astrocytes in the CNS, non-myelinating Schwann cells in the PNS, and enteric glial cells1.

        GFAP has a structural organization that is typical to class III IF proteins: it has a head, rod, and tail domains. The N-terminal head domain is important for filament formation and the C-terminal domain is important for oligomerization2.

        GFAP is encoded by a single gene mapped to human chromosome 17q21. To date, 10 isoforms/splice variants have been identified. GFAP is tightly regulated: both at mRNA transcription level and by phosphorylation and other post-translational modifications. A number of growth factors such as CNTF, FGF and TGF-β can induce GFAP gene transcription activation leading to increased GFAP protein levels3.

        Single nucleotide polymorphism (SNP) in GFAP results in the formation of Rosenthal fibers that cause Alexander Disease, hence, GFAP is a potential drug target for the treatment of this disease. A number of GFAP mutations were found in the coding and in the promoter regions of Alexander disease patients4.

        GFAP gene activation and protein induction appear to play a critical role in astroglia cell activation (astrogliosis) following CNS injuries and neurodegeneration. GFAP protein and its breakdown products are rapidly released into biofluids following traumatic brain and spinal cord injuries and stroke, making them strong candidate biomarkers for such neurological disorders5.

    Application key:

    CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IFC- Indirect flow cytometry, IF- Immunofluorescence, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot

    Species reactivity key:

    H- Human, M- Mouse, R- Rat
    Last update: 10/11/2019

    Anti-GFAP Antibody (#AFP-001) is a highly specific antibody directed against an epitope of the rat Glial fibrillary acidic protein. The antibody can be used in western blot and immunohistochemistry applications. It has been designed to recognize GFAP from rat and mouse samples. The antibody will not recognize human GFAP.

    For research purposes only, not for human use